Streetbeat News

Products Services

AGYS

Agilysys, Inc. has announced the provision of on-site premier support for its InfoGenesis Point-of-Sale system at Melbourne & Olympic Parks, aiming to enhance customer experience and operational efficiency.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:05 pm

HA

SABR

Sabre Corporation and Hawaiian Airlines have entered into a multi-year distribution agreement, which also resolves previous litigation between the two companies. The terms of the agreement were not disclosed. The deal allows travel agencies using Sabre's global distribution system to access Hawaiian Airlines' content, including NDC and traditional EDIFACT formats.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 10:49 pm

BTC-USD

ETH-USD

MATIC-USD

Former President Donald Trump has launched a third NFT collection, 'The MugShot Edition,' which includes physical editions and Bitcoin Ordinals. The collection, minted on the Polygon network, can be purchased with Ethereum or a credit card. Buyers of 100 NFTs receive a Bitcoin Ordinal and other perks, such as dinner gala invitations at Mar-a-Lago. The first two collections sold out, but the third has not, with 47,479 of 100,000 NFTs sold. The floor price of the first collection increased after Trump's early lead in the 2024 Republican nomination.

Portfolio Pulse from Chris Katje

January 18, 2024 | 10:28 pm

FUV

Arcimoto has signed an exclusive contract manufacturing agreement with Ellectramobilys, a French corporation, to produce the Muses Gen1 300, a light electric utility vehicle. This agreement is detailed in an 8-K filing.

Portfolio Pulse from Charles Gross

January 18, 2024 | 10:05 pm

AXGN

Axogen announced positive topline results from its REPOSE clinical trial for AxoGuard Nerve Cap, meeting its primary endpoint for pain reduction as measured by the Visual Analog Scale.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 10:01 pm

META

NVDA

Mark Zuckerberg, CEO of Meta Platforms Inc. (META), announced the company's major AI initiatives, focusing on integrating AI research efforts, developing general intelligence, committing to open-source technology, and investing in infrastructure with Nvidia Corp. (NVDA) GPUs. Meta is working on projects like Llama 3 and plans to integrate AI into new devices such as glasses. Following the announcement, META shares rose 2.1%, nearing all-time highs.

Portfolio Pulse from Piero Cingari

January 18, 2024 | 9:45 pm

GHRS

GH Research has been granted a European patent for all mebufotenin and mebufotenin salt products used in treating Major Depressive Disorder and Treatment-Resistant Depression. This patent strengthens the company's intellectual property position in Europe and could potentially enhance its competitive edge in the market for depression treatments.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 9:31 pm

AA

ABAT

IDR

BMO Capital analyst Katja Jancic downgraded Alcoa Corporation's (AA) price target from $30 to $29 following a Q4 earnings report showing a loss and revenue decline. Idaho Strategic Resources (IDR) reported its best year with significant revenue and gold production increases. American Battery Technology Company (ABAT) announced an upgraded resource classification for its Tonopah Flats Lithium Project, indicating a stronger potential for commercialization with a substantial increase in lithium resource size and higher confidence levels.

Portfolio Pulse from Austin DeNoce

January 18, 2024 | 9:31 pm

NVRO

Nevro Corp. (NYSE:NVRO) announced that Carelon Healthcare will expand coverage for spinal cord stimulation (SCS) for painful diabetic neuropathy (PDN), effective April 14. This policy change increases PDN patient coverage by nearly 43 million lives, including those under Anthem Blue Cross and other plans. Nevro's 10 kHz Therapy, an FDA-approved SCS system for PDN, will be more accessible. The expansion is supported by clinical trial data and is expected to continue with other health plans.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 9:19 pm

IKNA

Ikena Oncology, Inc. (NASDAQ:IKNA) announced a strategic shift towards advancing its lead oncology assets, IK-930 and IK-595, with a workforce reduction of about 35%. The company ended 2023 with approximately $175 million in cash, extending its financial runway into the second half of 2026. IK-930's optimized formulation is now in the clinic, with additional data expected in 2H 2024. The first cohort for IK-595 has been treated and cleared the safety evaluation. The reallocation of resources from discovery to clinical development is aimed at maximizing impact and driving advancements in cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 9:14 pm